<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210558</url>
  </required_header>
  <id_info>
    <org_study_id>Version 7</org_study_id>
    <nct_id>NCT03210558</nct_id>
  </id_info>
  <brief_title>Study of Testosterone and Athlete Response</brief_title>
  <acronym>STAR</acronym>
  <official_title>Effects of Moderately Increased Testosterone Concentration on Physical Performance and Behaviour in Healthy Women - a Double-blind, Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish School of Sport and Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial objectives and purpose: The primary aim is to study the effects of moderately increased
      testosterone concentration on aerobic performance (endurance time to exhaustion), and
      secondary aims to investigate the effects on submaximal work on treadmill, muscle strength,
      body composition, behaviour and well-being, blood parameters, steroid hormone profile,
      gynecological parameters and skeletal muscle parameters in young healthy women in a
      double-blind, randomized, placebo-controlled trial.

      Treatment: Ten weeks of transdermal treatment with testosterone cream 10 mg daily or placebo
      cream in a randomized design (1:1).

      Primary outcome: Aerobic performance (endurance time to exhaustion)

      Secondary outcomes:

        1. Submaximal work on treadmill (oxygen uptake, ventilation, heart rate, blood lactate and
           subjective rate of exhaustion)

        2. Muscle strength (Cybex apparatus, force transducer, counter movement jump)

        3. Body composition (Dual X-ray Absorptiometry: muscle mass, fat mass, bone mass)

        4. Behaviour and well-being (Quality of life, Profile of mood state, Confidence
           Questionnaire, Aggression Questionnaire)

        5. Blood parameters (hemoglobin, hematocrit, reticulocytes, ferritin, CRP)

        6. Steroid hormone profile in blood and urine

        7. Gynecological evaluation (ovarian and endometrial variables on ultrasound)

        8. Skeletal muscle morphology, metabolic enzymes and muscle protein synthesis

      Study population: Fifty healthy menstruating women will be included in the study and
      randomized to treatment with testosterone or placebo. Inclusion criteria: 18-35 yrs of age;
      body mass index (BMI) 19-25; non-smoking; a moderate to high self-reported level of
      recreational physical activity; not taking hormonal contraception and willing to use highly
      efficient non-hormonal contraception during the study (intrauterine device, bilateral tubal
      occlusion, vasectomised partner, same-sex partner, or sexual abstinence); accepting to not
      participate in any sports competitive event during the study period plus one month. Exclusion
      criteria: the presence of cardiovascular, liver, biliary or renal disease; hyperlipidemia;
      uncontrolled high blood pressure; endocrinological disorder; oligomenorrhea (menstrual
      intervals of more than 6 weeks) or amenorrhea (no menstruation for at least 3 months);
      pregnancy; a history of thromboembolic disorder; any malignancy; and intake of hormonal
      contraception the last two months prior to the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A double-blind, randomized, placebo-controlled, phase II trial of in total 50 women randomized to two parallel groups (1:1): Group A treated with transdermal testosterone or Group B treated with placebo for ten weeks.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The testosterone cream and the placebo cream will be of identical appearance and will have the same texture to maintain double blind treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Aerobic performance</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in endurance exercise time to exhaustion on bicycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Submaximal work on treadmill</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in oxygen uptake (L/min, mL/kg x min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength and endurance</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in peak muscle strength (N) and strength endurance (time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contractive functions</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in peak torque (Nm/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional power development</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in peak power output (N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in muscle mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellbeing</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in wellbeing (PGWB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in mood (POMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confidence</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in confidence (Confidence Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggression</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in aggression (Aggression Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in blood parameters (hemoglobin, hematocrit, reticulocytes, ferritin, CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid hormone profile in blood and urine</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in steroid hormones and metabolites in blood (testosterone, dihydrotestosterone, androstenedione, estradiol, dehydroepiandrosterone and its sulfate, cortisol, progesterone, other reproductive hormones (LH, FSH, AMH), binding protein (SHBG) and steroid hormones and metabolites in urine (estrone, estrone sulfate, androsterone glucuronide, 5α androstane-3α, 17β-diol 17-glucuronide, androst-5-ene-diol-3β, 17β-diol, testosterone, androstenedione, epitestosterone, androsterone, etiocholanolone).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gynecological evaluation</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in ultrasound assessments of the endometrium (mm) and ovaries (volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle</measure>
    <time_frame>Baseline and 10 weeks of treatment</time_frame>
    <description>Change in morphology and concentration of metabolic enzymes (HAD, SC), markers of muscle protein synthesis (mTOR, p70), as well as markers from the muscle atrophy pathway (MABbx, MuRF-1)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Athletic Performance</condition>
  <condition>Testosterone</condition>
  <condition>Women's Health: Female Athlete/Female Athlete Triad</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone cream 1% (Andro-Feme® )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone cream 1% (Andro-Feme® )</intervention_name>
    <description>Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria are: healthy menstruating women; 18-35 yrs of age; BMI 19-25;
        non-smoking; having a moderate to high self-reported level of recreational physical
        activity (minimum of three hours of endurance and/or strength training per week); not
        taking hormonal contraception; and willing to use highly efficient non-hormonal
        contraception during the study such as:

          -  Intrauterine device

          -  Bilateral tubal occlusion

          -  Vasectomised partner

          -  Same-sex partner

          -  Sexual abstinence

        Exclusion criteria are: the presence of cardiovascular, liver, biliary or renal disease;
        hyperlipidemia; uncontrolled high blood pressure; endocrinological disorder; oligomenorrhea
        (menstrual intervals of more than 6 weeks) or amenorrhea (no menstruation for at least 3
        months); pregnancy; a history of thromboembolic disorder; any malignancy; and intake of
        hormonal contraception the last two months prior to the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelica Lindén Hirschberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angelica Lindén Hirschberg</last_name>
    <phone>+ 46 70 255 99 24</phone>
    <email>angelica.linden-hirschberg@sll.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica L Hirschberg, Professor</last_name>
      <phone>+46 8 517 733 26</phone>
      <email>angelica.linden-hirschberg@karolinska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bermon S, Ritzén M, Hirschberg AL, Murray TH. Are the new policies on hyperandrogenism in elite female athletes really out of bounds? Response to &quot;out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes&quot;. Am J Bioeth. 2013;13(5):63-5. doi: 10.1080/15265161.2013.776129.</citation>
    <PMID>23557056</PMID>
  </reference>
  <reference>
    <citation>Bermon S, Garnier PY, Hirschberg AL, Robinson N, Giraud S, Nicoli R, Baume N, Saugy M, Fénichel P, Bruce SJ, Henry H, Dollé G, Ritzen M. Serum androgen levels in elite female athletes. J Clin Endocrinol Metab. 2014 Nov;99(11):4328-35. doi: 10.1210/jc.2014-1391. Epub 2014 Aug 19.</citation>
    <PMID>25137421</PMID>
  </reference>
  <reference>
    <citation>Buss AH, Perry M. The aggression questionnaire. J Pers Soc Psychol. 1992 Sep;63(3):452-9.</citation>
    <PMID>1403624</PMID>
  </reference>
  <reference>
    <citation>Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005 Jun;83(6):1717-23.</citation>
    <PMID>15950641</PMID>
  </reference>
  <reference>
    <citation>Davis S, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, Stuckey BG, Wlodarczyk J, Gard'ner K, Humberstone A. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. 2008 Apr 15;148(8):569-77.</citation>
    <PMID>18413618</PMID>
  </reference>
  <reference>
    <citation>Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab. 2009 Dec;94(12):4907-13. doi: 10.1210/jc.2009-1523. Epub 2009 Oct 22.</citation>
    <PMID>19850682</PMID>
  </reference>
  <reference>
    <citation>El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric. 2007 Aug;10(4):335-43.</citation>
    <PMID>17653960</PMID>
  </reference>
  <reference>
    <citation>Fénichel P, Paris F, Philibert P, Hiéronimus S, Gaspari L, Kurzenne JY, Chevallier P, Bermon S, Chevalier N, Sultan C. Molecular diagnosis of 5α-reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism. J Clin Endocrinol Metab. 2013 Jun;98(6):E1055-9. doi: 10.1210/jc.2012-3893. Epub 2013 Apr 30.</citation>
    <PMID>23633205</PMID>
  </reference>
  <reference>
    <citation>Fooladi E, Reuter SE, Bell RJ, Robinson PJ, Davis SR. Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause. 2015 Jan;22(1):44-9. doi: 10.1097/GME.0000000000000259.</citation>
    <PMID>24845394</PMID>
  </reference>
  <reference>
    <citation>Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause. 2003 Sep-Oct;10(5):390-8.</citation>
    <PMID>14501599</PMID>
  </reference>
  <reference>
    <citation>Gooren LJ, Bunck MC. Transsexuals and competitive sports. Eur J Endocrinol. 2004 Oct;151(4):425-9. Review.</citation>
    <PMID>15476439</PMID>
  </reference>
  <reference>
    <citation>Hagmar M, Berglund B, Brismar K, Hirschberg AL. Hyperandrogenism may explain reproductive dysfunction in olympic athletes. Med Sci Sports Exerc. 2009 Jun;41(6):1241-8. doi: 10.1249/MSS.0b013e318195a21a.</citation>
    <PMID>19461542</PMID>
  </reference>
  <reference>
    <citation>Meriggiola MC, Jannini EA, Lenzi A, Maggi M, Manieri C. Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol. 2010 May;162(5):831-3. doi: 10.1530/EJE-09-1091. Epub 2010 Feb 11.</citation>
    <PMID>20150325</PMID>
  </reference>
  <reference>
    <citation>Huang G, Basaria S, Travison TG, Ho MH, Davda M, Mazer NA, Miciek R, Knapp PE, Zhang A, Collins L, Ursino M, Appleman E, Dzekov C, Stroh H, Ouellette M, Rundell T, Baby M, Bhatia NN, Khorram O, Friedman T, Storer TW, Bhasin S. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause. 2014 Jun;21(6):612-23. doi: 10.1097/GME.0000000000000093.</citation>
    <PMID>24281237</PMID>
  </reference>
  <reference>
    <citation>Jovanovic H, Kocoska-Maras L, Rådestad AF, Halldin C, Borg J, Hirschberg AL, Nordström AL. Effects of estrogen and testosterone treatment on serotonin transporter binding in the brain of surgically postmenopausal women--a PET study. Neuroimage. 2015 Feb 1;106:47-54. doi: 10.1016/j.neuroimage.2014.11.003. Epub 2014 Nov 11.</citation>
    <PMID>25462800</PMID>
  </reference>
  <reference>
    <citation>Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987 Feb;8(1):1-28. Review.</citation>
    <PMID>3549275</PMID>
  </reference>
  <reference>
    <citation>Notelovitz M. Androgen effects on bone and muscle. Fertil Steril. 2002 Apr;77 Suppl 4:S34-41. Review.</citation>
    <PMID>12007900</PMID>
  </reference>
  <reference>
    <citation>Rickenlund A, Carlström K, Ekblom B, Brismar TB, von Schoultz B, Hirschberg AL. Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea or amenorrhea in female athletes and may improve physical performance. Fertil Steril. 2003 Apr;79(4):947-55.</citation>
    <PMID>12749436</PMID>
  </reference>
  <reference>
    <citation>Slayden SM. Risks of menopausal androgen supplementation. Semin Reprod Endocrinol. 1998;16(2):145-52. Review.</citation>
    <PMID>9711680</PMID>
  </reference>
  <reference>
    <citation>Turpeinen U, Linko S, Itkonen O, Hämäläinen E. Determination of testosterone in serum by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest. 2008;68(1):50-7. Epub 2007 Jun 24.</citation>
    <PMID>17852804</PMID>
  </reference>
  <reference>
    <citation>Zang H, Carlström K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil Steril. 2006 Jul;86(1):136-44. Epub 2006 Jun 5.</citation>
    <PMID>16750207</PMID>
  </reference>
  <reference>
    <citation>Zang H, Sahlin L, Masironi B, Eriksson E, Lindén Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab. 2007 Jun;92(6):2169-75. Epub 2007 Mar 6.</citation>
    <PMID>17341565</PMID>
  </reference>
  <reference>
    <citation>Zethraeus N, Kocoska-Maras L, Ellingsen T, von Schoultz B, Hirschberg AL, Johannesson M. A randomized trial of the effect of estrogen and testosterone on economic behavior. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6535-8. doi: 10.1073/pnas.0812757106. Epub 2009 Apr 6.</citation>
    <PMID>19366676</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Angelica Lindén Hirschberg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>female athletes, testosterone, physical performance, body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Female Athlete Triad Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

